about
Combinations of insulin and oral hypoglycaemic agents for people with type 2 diabetes mellitus on insulin treatmentInsulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitusTroglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasiaPolymorphism in the sorbin and SH3-domain-containing-1 (SORBS1) gene and the risk of brain infarction in the Japanese population: the Fukuoka Stroke Registry and the Hisayama study.Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies.A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.Glycemic control and complications of diabetes mellitus.Insulin and atherosclerosis: villain, accomplice, or innocent bystander?Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes?Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?Defects in insulin action in chronic heart failure.High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis.Cardiovascular impact of drugs used in the treatment of diabetesCardiovascular disease in Navajo Indians with type 2 diabetesThe effect of polyhydroxylated alkaloids on maltase-glucoamylaseLong-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.Changes in glucose and fat metabolism in response to the administration of a hepato-preferential insulin analog.The triglyceride connection in atherosclerosis.Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune Children's StudyPercutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents.Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension, and accelerated atherosclerosis.Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy.Early insulin resistance in severe trauma without head injury as outcome predictor? A prospective, monocentric pilot study.Ischemic Stroke and Its Risk Factors in a Registry-Based Large Cross-Sectional Diabetic Cohort in a Country Facing a Diabetes EpidemicHyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice.Type 2 diabetic patients with ischemic stroke: decreased insulin sensitivity and decreases in antioxidant enzyme activity are related to different stroke subtypes.Abnormalities of cholesterol metabolism in diabetes.Continuous subcutaneous insulin infusion versus multiple daily injections.The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women's usual cardiac protectionRelationship of glycemic control, exogenous insulin, and C-peptide levels to ischemic heart disease mortality over a 16-year period in people with older-onset diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).Relationship between extent and complexity of coronary artery disease and different left ventricular geometric patterns in patients with coronary artery disease and hypertension.The cardiovascular effects of insulin.Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study.New treatments for patients with type 2 diabetes mellitusInsulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.Effect of diet and moderate exercise on central obesity and associated disturbances, myocardial infarction and mortality in patients with and without coronary artery disease.The prominent role of p38 mitogen-activated protein kinase in insulin-mediated enhancement of VCAM-1 expression in endothelial cells.Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism.Differential effects of growth hormone and insulin-like growth factor I on human endothelial cell migration.
P2860
Q24243407-3EA994D3-110E-4B12-9151-D6220D0049B9Q24246084-3ABC60D8-32CC-43E5-9EC0-F02AE08E8F9DQ28379241-341835C7-9007-4FD6-9A80-BC4619DE73AFQ30157712-B00E7F16-9909-418F-9A9A-D14805431D47Q30941905-2B760911-35F5-42DC-ACC5-AF654B3E0F24Q33561396-476AB070-4D97-4DEA-9A64-80B2D794D23EQ33608578-CBADC818-7BBF-4598-8FE8-E55CA6264BA6Q33612890-DD59B190-1265-47C2-A929-A315C4DFF4F4Q33833060-D5E78E13-E024-4383-B469-5836F42D0EC8Q34023548-749702AC-21FB-44E6-8FC8-F7A6CCA463E3Q34166305-B8C983D7-E493-4CDE-AD44-4BD4C577688FQ34249521-0137D8CC-2517-4588-9115-D185C87803E7Q34383575-348E4473-D707-40EC-8FE7-08F8010C6689Q34406173-C82A3FE2-1CDF-45F0-8EB6-9D399D176CB2Q34962981-77E01167-669F-4965-AE13-A4E05E82009AQ35044151-C2DDC886-A3BD-4781-84F4-6C535432AD0CQ35360786-7F23F1C6-B1B4-4E1E-97EE-A2C61FB23CB2Q35466693-19B9B064-52CE-4546-881E-96A9595FD80EQ35757053-E0826A22-ED35-4DB0-94A9-8DF4415E74B8Q36216817-5B3E7375-2909-4065-880C-B71275FC12F1Q36339952-6D63F563-01EC-4091-AAA8-D654935E157FQ36378641-E4CF1430-EC03-4A9F-88AF-EDC7483FF06AQ36541579-A2DBC05B-5095-4FC3-A533-887234505FD5Q36632878-1DFC3B11-8DF9-48F0-AAFF-5229DBBB9A0EQ36806457-3D19218B-FD6E-4DED-A0CA-BD3F545D4065Q36969611-95321617-A224-4517-9553-F9B0F31BA75BQ37039943-E07B1A75-6B0E-40D3-B4DE-64E680AC9C2FQ37194898-C9B058BC-FA49-4333-A491-0CFC37065258Q37262556-F1A63740-0AA2-40F5-849B-FBE513F2F31AQ37412202-CE7A4486-28A7-4668-AF80-5773AA74CF81Q37680567-06441C39-5022-4A6D-A9DA-DEE31B36A3BEQ38217755-6209B41D-91BA-4ACE-9CE0-CE4C60A09B4FQ38258938-3830F2CA-9249-41ED-8084-6F468D3321C8Q38482584-3038FBB9-35DD-44B5-8221-EC99C506991DQ38646293-74BD4A3F-E553-402C-A922-07A0EAAB5371Q38957754-BA5B7011-4DBD-4E23-A4C0-820A4817A719Q39437303-99324E8A-B7AC-4665-8084-AC13536D8A00Q40078479-F569D6E9-37DF-4024-BA88-CC4F26E3DF28Q40623938-67AECF52-1E5F-40A2-865C-1490222CFF84Q40814967-7EF2EA9F-F1D6-4CCF-8BFC-1CE9914CC584
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Insulin and atheroma. 20-yr perspective.
@en
Insulin and atheroma. 20-yr perspective.
@nl
type
label
Insulin and atheroma. 20-yr perspective.
@en
Insulin and atheroma. 20-yr perspective.
@nl
prefLabel
Insulin and atheroma. 20-yr perspective.
@en
Insulin and atheroma. 20-yr perspective.
@nl
P356
P1433
P1476
Insulin and atheroma. 20-yr perspective.
@en
P2093
P304
P356
10.2337/DIACARE.13.6.631
P407
P577
1990-06-01T00:00:00Z